Orgel E, Knight KR, Villaluna D, Krailo M, Esbenshade AJ, Sung L, Freyer DR. Reevaluation of sodium thiosulfate otoprotection using the consensus International Society of Paediatric Oncology Ototoxicity Scale: A report from the Children’s Oncology Group study ACCL0431. Pediatr Blood Cancer. 2023 Jul 7;:e30550. doi: 10.1002/pbc.30550. [Epub ahead of print] PubMed PMID: 37416942; PubMed Central PMCID: PMC10771531.
Study ID Citation
Abstract
In two randomized trials (ACCL0431, SIOPEL-6), sodium thiosulfate (STS) demonstrated efficacy in preventing cisplatin-induced hearing loss (CIHL). However, the measures used in those trials have been superseded by the consensus Society of International Paediatric Oncology (SIOP) Ototoxicity Scale. To provide benchmark data for STS efficacy when using this contemporary scale, we reanalyzed ACCL0431 hearing outcomes with the SIOP scale and using multiple timepoints. As compared to the control arm, STS significantly reduced CIHL when assessed by the SIOP scale across these different approaches. These results provide critical data to inform treatment discussions and support future potential trial designs comparing otoprotectants.